Literature DB >> 24729772

Statin-induced cholestatic hepatitis: confirmed on rechallenge.

Sam Kerzner1, Nenita Irabagon1, Charles Berkelhammer1.   

Abstract

Entities:  

Year:  2013        PMID： 24729772      PMCID： PMC3983980     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  20 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.

Authors:  James M McKenney; Michael H Davidson; Terry A Jacobson; John R Guyton
Journal:  Am J Cardiol       Date:  2006-02-28       Impact factor: 2.778

3.  Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.

Authors:  Raj Vuppalanchi; Evegenia Teal; Naga Chalasani
Journal:  Am J Med Sci       Date:  2005-02       Impact factor: 2.378

4.  The adaptive response (drug tolerance) helps to prevent drug-induced liver injury.

Authors:  James H Lewis
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-05

5.  Statin treatment in patients with elevated liver enzymes: pitch to proceed.

Authors:  Charles Berkelhammer; Edgar V Lerma
Journal:  J Clin Lipidol       Date:  2012-05-22       Impact factor: 4.766

Review 6.  Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

Authors:  Rossana M Calderon; Luigi X Cubeddu; Ronald B Goldberg; Eugene R Schiff
Journal:  Mayo Clin Proc       Date:  2010-04       Impact factor: 7.616

Review 7.  Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review.

Authors:  Alexey Sorokin; Jennifer L Brown; Paul D Thompson
Journal:  Atherosclerosis       Date:  2007-01-22       Impact factor: 5.162

Review 8.  3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.

Authors:  Maria Tzefos; Jacqueline L Olin
Journal:  J Clin Lipidol       Date:  2011-06-28       Impact factor: 4.766

Review 9.  Risks associated with statin therapy: a systematic overview of randomized clinical trials.

Authors:  Amir Kashani; Christopher O Phillips; JoAnne M Foody; Yongfei Wang; Sandeep Mangalmurti; Dennis T Ko; Harlan M Krumholz
Journal:  Circulation       Date:  2006-12-11       Impact factor: 29.690

10.  Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

Authors:  Naga Chalasani; Hisham Aljadhey; Joe Kesterson; Michael D Murray; Stephen D Hall
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682
View more
  3 in total

Review 1.  Statins and liver injury.

Authors:  Manish Thapar; Mark W Russo; Herbert L Bonkovsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

Review 2.  Statin-induced Liver Injury Patterns: A Clinical Review.

Authors:  Leon D Averbukh; Alla Turshudzhyan; David C Wu; George Y Wu
Journal:  J Clin Transl Hepatol       Date:  2022-01-10

3.  Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.

Authors:  Wen-Kai Li; Huan Li; Yuan-Fu Lu; Ying-Ying Li; Zidong Donna Fu; Jie Liu
Journal:  PeerJ       Date:  2017-05-18       Impact factor: 2.984
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.